Nivolumab plus ipilimumab induced durable responses among a small cohort of women with high tumor mutational burden metastatic HER2-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.Researchers involved with the phase 2 NIMBUS trial observed no new safety concerns with the combination.